April 23, 2021
Tokushima-based biotech Delta-Fly Pharma and partner Nippon Chemiphar said on April 22 that a PII clinical trial got underway in Japan for their investigational tumor microenvironment therapy DFP-17729 for the treatment of terminal pancreatic cancer. The PII study is designed...read more